One in four Indians faces silent genetic threat to heart health, shows study
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Â
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…